Jefferies & Co downgrades Gilead Sciences (GILD) to Hold
Jefferies & Co downgrades Gilead Sciences (Nasdaq: GILD) from Buy to Hold. Price target $56.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need.
Related Categories
DowngradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
